| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 450 | 2020 |
| Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer S Raghavan, PS Winter, AW Navia, HL Williams, A DenAdel, KE Lowder, ... Cell 184 (25), 6119-6137. e26, 2021 | 246 | 2021 |
| Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11-and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status B Ricciuti, K Arbour, J Lin, A Vajdi, M Tolstorukov, L Hong, J Zhang, ... Journal of Thoracic Oncology 16 (3), S341, 2021 | 186 | 2021 |
| Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC G Recondo, M Bahcall, LF Spurr, J Che, B Ricciuti, GC Leonardi, YC Lo, ... Clinical Cancer Research 26 (11), 2615-2625, 2020 | 146 | 2020 |
| Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L) 1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer B Ricciuti, G Recondo, LF Spurr, YY Li, G Lamberti, D Venkatraman, ... Clinical Cancer Research 26 (15), 4135-4142, 2020 | 114 | 2020 |
| Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer G Lamberti*, LF Spurr*, Y Li, B Ricciuti, G Recondo, R Umeton, M Nishino, ... Annals of Oncology, 2020 | 85 | 2020 |
| SMARCA4 and other SWItch/sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition JV Alessi, B Ricciuti, LF Spurr, H Gupta, YY Li, C Glass, M Nishino, ... Journal of Thoracic Oncology 16 (7), 1176-1187, 2021 | 67 | 2021 |
| Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors S Abou Alaiwi, AH Nassar, W Xie, Z Bakouny, JE Berchuck, DA Braun, ... Cancer immunology research 8 (8), 1075-1084, 2020 | 60 | 2020 |
| CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer SI Gutiontov, WT Turchan, LF Spurr, SJ Rouhani, CS Chervin, ... Scientific reports 11 (1), 20059, 2021 | 56 | 2021 |
| FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma JM Cleary, S Raghavan, Q Wu, YY Li, LF Spurr, HV Gupta, DA Rubinson, ... Cancer discovery 11 (10), 2488-2505, 2021 | 52 | 2021 |
| Discovery and features of an alkylating signature in colorectal cancer C Gurjao, R Zhong, K Haruki, YY Li, LF Spurr, H Lee-Six, B Reardon, ... Cancer discovery 11 (10), 2446-2455, 2021 | 51 | 2021 |
| Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade LF Spurr, CA Martinez, W Kang, M Chen, Y Zha, R Hseu, SI Gutiontov, ... Nature cancer 3 (12), 1498-1512, 2022 | 32 | 2022 |
| Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers harboring loss of chromosome 18q or 16q JE Neggers, BR Paolella, A Asfaw, MV Rothberg, TA Skipper, A Yang, ... Cell reports 33 (11), 2020 | 30 | 2020 |
| Cancer aneuploidies are shaped primarily by effects on tumour fitness J Shih, S Sarmashghi, N Zhakula-Kostadinova, S Zhang, Y Georgis, ... Nature 619 (7971), 793-800, 2023 | 28 | 2023 |
| Quantification of aneuploidy in targeted sequencing data using ASCETS LF Spurr, M Touat, AM Taylor, AM Dubuc, J Shih, DM Meredith, ... Bioinformatics 37 (16), 2461-2463, 2021 | 27 | 2021 |
| Genomic characterization of de novo metastatic breast cancer AC Garrido-Castro, LF Spurr, ME Hughes, YY Li, AD Cherniack, P Kumari, ... Clinical Cancer Research 27 (4), 1105-1118, 2021 | 27 | 2021 |
| Tumor aneuploidy predicts survival following immunotherapy across multiple cancers LF Spurr, RR Weichselbaum, SP Pitroda Nature genetics 54 (12), 1782-1785, 2022 | 24 | 2022 |
| Systematic pan-cancer analysis of somatic allele frequency LF Spurr, M Li, N Alomran, Q Zhang, P Restrepo, M Movassagh, ... Scientific reports 8 (1), 1-12, 2018 | 23 | 2018 |
| Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions H Singh, YY Li, LF Spurr, AB Shinagare, R Abhyankar, E Reilly, LK Brais, ... Clinical Cancer Research, 2021 | 21 | 2021 |
| Estimating the Allele-Specific Expression of SNVs From 10× Genomics Single-Cell RNA-Sequencing Data H Liu, P Bousounis, L Spurr, N Alomran, H Ibeawuchi, J Sein, ... Genes 11 (3), 240, 2020 | 21 | 2020 |
Andrew CherniackBroad InstituteVerified email at broadinstitute.org
